NEW VIDEO - Dr Roy: Phase 2 trial of selective depletion of recipient-alloreactive T-cells (ATIR) in AML and ALL At the 2014 American Society of #Hematology (ASH) Annual Meeting, Dr Denis-Claude Roy (University of Montreal, Montreal, Canada) discusses a phase II trial that evaluated selective photodepletion of recipient-alloreactive T-cells (ATIR) for haploidentical haematopoietic stem cell transplant in patients with acute lymphoblastic leukaemia (ALL) and acute myeloid #leukaemia (AML). ATIR does not cause any grade III/IV graft-versus-host disease (GvHD) and demonstrates promising treatment-related mortality and overall survival rates. youtu.be/NDeh-gbZ8-Y For more exclusive content from ASH 2014 subscribe to our EMJ YouTube channel - https://youtube/channel/UCaOYR5zTz5XcB-ZGNwj467g
Posted on: Thu, 18 Dec 2014 15:59:02 +0000
Trending Topics
Recently Viewed Topics
© 2015